Current and emerging therapies for the management of chronic inflammation in asthma

American Journal of Health-System Pharmacy

Volumn 60, Issue 19, 2003, Pages 1949-1961

  DeKorte, Carrie J ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Antibodies; Antiinflammatory agents; Asthma; Combined therapy; Cytokine antagonists; Immunomodulating agents; Inhalers; Leukotriene antagonists; National Asthma Education and Prevention Program; National Institutes of Health; Pharmacoeconomics

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DEXAMETHASONE; GLUCOCORTICOID; HMR 4011 A; IPL 576 092; LEUKOCYTE SUPPRESSING ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ASTHMA; CHRONIC INFLAMMATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; GLAUCOMA; HUMAN; IMMUNOMODULATION; LEUKOCYTE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CHRONIC DISEASE; DRUG COMBINATION; METERED DOSE INHALER; PRACTICE GUIDELINE;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; METERED DOSE INHALERS; PRACTICE GUIDELINES;

EID: 1542544443     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.19.1949     Document Type: Review

References (89)

1. National Heart, Lung, and Blood Institute. Morbidity and mortality chart book, May 2002. www.nhlbi.nih.gov/resources/docs/02_chtbk.pdf (accessed 2002 Nov 1 ).
2. Centers for Disease Control and Prevention. Forecasted state-specific estimates of self-reported asthma prevalence-United States, 1998. Morb Mortal Wkly Rep. 1998; 47:1022-5.
3. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. J Allergy Clin Immunol. 2000; 106:17-26.
4. National Asthma Education and Prevention Program. Quick reference NAEPP expert panel report guidelines for the diagnosis and management of asthma-update on selected topics, 2002. NIH publication no. 02-5075. www.nhlbi. nih.gov/guidelines/asthma/asthsumm. htm (accessed 2002 Nov 1).
5. Ledford DK. Inflammation and asthma: here, there, everywhere. Ann Allergy Asthma Immunol. 2002; 89:346-7. Editorial.
6. O'Conner R. Current approaches to asthma management: assessing clinical and economic evidence. J Manag Care Pharm. 2002; 8(suppl 5):8-17.
7. Marx J, Hockberger R, Walls R, eds. Rosen's emergency medicine: concepts and clinical practice. 5th ed. New York: Mosby, 2002:941-2.
8. Wardlaw AJ, Brightling C, Green R et al. Eosinophils in asthma and other allergic diseases. Br Med Bull. 2000; 56:985-1003.
9. Crimi E, Spanevello A, Neri M et al. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med. 1998; 157:4-9.
10. Pizzichini MM, Pizzichini E, Clelland L et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J. 1999; 13:15-21.
11. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002; 360:1715-21.
12. Chung KF. Anti-IgE therapy of asthma. Curr Opin Investig Drugs. 2002; 3:1157-60.
13. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18:157-62.
14. Pollart SM, Chapman MD, Fiocco GP et al. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol. 1989; 83:875-82.
15. Burrows B, Martinez FD, Halonen M et al. Association of asthma with serum IgE levels and skin-test to reactivity to allergens. N Engl J Med. 1989; 320:271-7.
16. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci. 1979; 76:4275-9.
17. Krawiec ME, Jarjour NJ. Leukotriene receptor antagonists. Semin Respir Crit Care Med. 2002; 23:399-410.
18. Turk A. Understanding the impact of asthma in the 21st century. J Manag Care Pharm. 2002; 8(suppl 5):3-7.
19. Wolf BL. The current landscape of asthma: a new geometry. Ann Allergy Asthma Immunol. 2002; 89:337-8. Editorial.
20. Busse WW, Nelson HS, Wolfe J et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075-80.
21. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106:1088-95.
22. Nielsen LP, Pedersen B, Faurschou P et al. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. Respir Med. 1999; 93:863-8.
23. Pederson S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997; 52(suppl 39):1-34.
24. Corticosteroid action and resistance in asthma. Proceedings of a meeting. Buckinghamshire, United Kingdom, October 1995. Am J Respir Crit Care Med. 1996; 154(2, pt. 2):S1-79.
25. Bhalay G, Sandham DA. Recent advances in corticosteroids for the treatment of asthma. Curr Opin Investig Drugs. 2002; 3:1149-56.
26. Szefler SJ, Martin RG, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002; 109:410-8.
27. Greening AP, Ind PW, Northfield M et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994; 344:219-24.
28. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997; 337:1405-11.
29. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001; 164(8, pt. I):1392-7.
30. Blais L, Ernst P, Boivin JF et al. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med. 1998; 158:126-32.
31. Suissa S, Ernst P, Benayoun S et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343:332-6.
32. Agency for Healthcare Research and Quality. Management of chronic asthma. September 2001. AHRQ publication no. 01-E043. www.ahrq.gov (accessed 2002 Nov 1).
33. Tattersfield AE, Knox AJ, Britoon JR et al. Asthma. Lancet. 2002; 360:1313-22.
34. Leung DY, Spahn JD, Szefier SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med. 2002; 23(4):387-98.
35. Chan MT, Leung DY, Szefler SJ et al. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998; 101:594-601.
36. Meltzer EO, Lockey RF, Friedman BF et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc. 2002; 77:437-45.
37. Laviolette M, Malmstrom K, Lu S et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999; 160:1862-8.
38. Virchow JC, Prasse A, Naya I et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000; 162:578-85.
39. Simons FE, Villa JR, Lee BW et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001; 138:694-8.
40. Armstrong EP, Malone DC. Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis. Pharmacotherapy. 2002; 22:1117-23.
41. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy. 2002; 22:166-74.
42. Stempel DA, Meyer JW, Stanford RH et al. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol. 2001; 107:94-8.
43. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol. 2002; 109:433-9.
44. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002; 324:14-30.
45. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol. 2002; 88:152-61.
46. Shields RL, Whether WR, Zioncheck K et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995; 107:308-12.
47. Corren J, Froehlich J, Schoenhoff M et al. Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAb-E25 (E25) in adults with moderate to severe asthma. J Allergy Clin Immunol. 1996; 97:245.
48. Marian M, Sun YN, Sinclair D et al. Clinical pharmacokinetics (PK) and IgE pharmacodynamics of omalizumab, a recombinant humanized monoclonal antibody to IgE. Clin Pharmacol Ther. 2001; 69:7. Abstract.
49. Bisburg D, Froehlich J, Schoenhoff M. A phase I, single-blind study to determine the safety, tolerance, pharmacokinetics and pharmacodynamics of anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) in adolescents and children with moderate to severe allergic asthma. Pediatr Res. 1996; 39(pt. 2):9A. Abstract.
50. Fick RB, Rohane PW, Gupta N et al. Antiinflammatory effects of a recombinant monoclonal anti-IgE (E25) in asthma. Am J Respir Crit Care Med. 2000; 161 (suppl):A199. Abstract.
51. Come J, Djukanovic R, Thomas L et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest. 1997; 99:879-87.
52. Xolair prescribing information. South San Francisco, CA: Genentech, Inc.; 2002.
53. Boulet LP, Chapman KR, Cote J et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997; 155:1835-40.
54. Milgrom H, Fick RB, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 1999; 341:1966-73.
55. MacGlashan DW Jr, Bochner BS, Adelman DC et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158:1438-45.
56. MacGlashan DW Jr, Xia HZ, Schwartz LB et al. IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcεRI in human basophils. J Leukoc Biol. 2001; 70:207-18.
57. Saini SS, MacGlashan DW Jr, Sterbinsky SA et al. Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE infusions is reversible in vitro and in vivo. J Immunol. 1999; 162:5624-30.
58. Soler M, Matz J, Townley RG et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respir J. 2001; 18:254-61.
59. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombination humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108:184-90.
60. Buhl R, Soler M, Matz J et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002; 20:73-8.
61. Protein Design Labs. Daclizumab. www.pdl.com/wt/sec.php3?page_name= clin_asthma_dac&return=clinical (accessed 2003 Jan 1).
62. Shames RS, Vexler V, Lane NM et al. The safety and pharmacokinetics of SB 2408683 (anti-IL-4 humanized monoclonal antibody) in patients with mild to moderate asthma. J Allergy Clin Immunol. 2001; 107:5316. Abstract.
63. Hart TK. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001; 108:250-7.
64. Leckie MJ, ten Brincke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000; 356:2144-8.
65. Kips JC, O'Connor BJ, Langley SJ et al. Results of a phase I trial with SCH55700, a humanized anti-IL-5 antibody in severe persistent asthma. Am J Resp Crit Care Med. 2000; 161:A505. Abstract.
66. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol. 2002; 42:81-98.
67. Iijima H, Tamura G, Hsiue TR et al. Suplatast tosilate inhibits late response and airway inflammation in sensitized guinea pigs. Am J Respir Crit Care Med. 1999; 160:331-5.
68. Matsumoto K, Hayakawa H, Ide K et al. Effects of suplatast tosilate on cytokine profile of bronchoalveolar cells in allergic inflammation of the lung. Respirology. 2002; 7:201-7.
69. Sano Y, Miyamoto T, Makin S. Antiinflammatory effect of suplatast tosilate on mild asthma. Chest. 1997; 112:862-3.
70. Yoshida M, Aizawa H, Inoue H et al. Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients. J Asthma. 2002; 39:545-52.
71. Tamaoki J, Kondo M, Sakai N et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Lancet. 2002; 356:273-8.
72. Kips JC, Tournoy KG, Pauwels RA. New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5. Eur Respir J. 2001; 17:499-506.
73. Borish LC, Nelson HS, Lanz MJ et al. Interleukin-4 receptor in moderate atopic asthma. Am J Respir Crit Care Med. 1999; 160:1816-23.
74. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest. 2002; 121:192S-6S.
75. Bundschuh DS, Eltze M, Barsig J et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharm Exp Ther. 2001; 292:280-90.
76. Hatzelmann A, Schudt C. Antiinflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharm Exp Ther. 2001; 297:267-79.
77. Reid P. Roflumilast. Curr Opin Investig Drugs. 2002; 3:1165-70.
78. Compton CH, Cedar E, Nieman RB et al. Ariflo improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids. Am J Respir Crit Care Med. 1999; 159:A522. Abstract.
79. Compton CH, Duggag M, Cedar E et al. Safety of Ariflo in a 12-month study of patients with asthma. Am J Respir Crit Care Med. 2000; 161:A200. Abstract.
80. Neiman RB, Fisher BD, Amit O et al. SB 207499 (Ariflo), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med. 1998; 157:A413. Abstract.
81. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis. 2002; 57:48-64.
82. Compton CH, Gubb J, Nieman R et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 2001; 358:265-70.
83. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995; 152 (suppl):S77-150.
84. British Thoracic Society COPD Guidelines Group of the Standards of Care Committee. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax. 1998; 52(suppl):S1-28.
85. National Lung Health Education Program Executive Committee. Strategies in preserving lung health and preventing COPD and associated diseases. Chest. 1998; 113(suppl):123S-63S.
86. Trifilieff A, Wyss D, Walker C et al. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo [1,2,5]oxadiazol-5-yl-[1,7] naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative with antiinflammatory activities. J Pharm Exp Ther. 2002; 301:241-8.
87. Billah MM, Cooper N, Minnicozzi M et al. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J Pharm Exp Ther. 2002; 302:127-37.
88. Inflazyme Pharmaceuticals, Ltd. www.inflazyme.com/news/news_ 05_12_03_body.pdf (accessed 2003 May 15).
89. Kuriakose N, Rebstein P, Bechard J et al. IPL576.092 is a novel steroidal antiinflammatory compound with a mechanism of action distinct from that of gucocorticoids. Paper presented at the American Academy of Asthma, Allergy, and Immunology 57th Annual Meeting, New Orleans, LA; 2001 Mar 18.